CBS 2019
CBSMD教育中心
English

经导管主动脉瓣置换

科研文章

荐读文献

Comparison of 1-Year Pre- And Post-Transcatheter Aortic Valve Replacement Hospitalization Rates: A Population-Based Cohort Study Infective Endocarditis After Transcatheter Aortic Valve Replacement Management of Asymptomatic Severe Aortic Stenosis: Evolving Concepts in Timing of Valve Replacement Risk of Coronary Obstruction and Feasibility of Coronary Access After Repeat Transcatheter Aortic Valve Replacement With the Self-Expanding Evolut Valve: A Computed Tomography Simulation Study Short Length of Stay After Elective Transfemoral Transcatheter Aortic Valve Replacement Is Not Associated With Increased Early or Late Readmission Risk Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation Infective endocarditis after transcatheter aortic valve implantation: a nationwide study Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement: JACC Review Topic of the Week Predictors and Clinical Outcomes of Next-Day Discharge After Minimalist Transfemoral Transcatheter Aortic Valve Replacement Single Versus Dual Antiplatelet Therapy Following TAVR: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Original Research10 June 2020

JOURNAL:Catheter Cardiovasc Interv. Article Link

Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement

J Sathananthan, P Green, M Finn et al. Keywords: -min walk test; aortic stenosis; TAVR

ABSTRACT

BACKGROUND - While slow gait speed is known to be associated with poor outcomes in patients at high surgical risk who undergo transcatheter aortic valve replacement (TAVR), the prognostic significance of slow gait speed in intermediate risk TAVR patients is poorly understood.

 

OBJECTIVES - We assessed the association between baseline 6min walk test (6MWT) performance and both 2year mortality and health status in intermediate risk patients undergoing TAVR as a part of the PARTNER II/S3i studies.

 

METHODS - The association of baseline 6MWT with mortality over 2years after TAVR was examined using Cox regression; both unadjusted and adjusted for age, left ventricular ejection fraction, coronary artery disease, pulmonary disease, renal insufficiency, and STS score. Patients were divided into four groups according to baseline 6MWT: unable to walk and in three equal tertiles of slow, medium, and fast walkers. Among surviving patients, improvement in 6MWT and quality of life were compared.

 

RESULTS - Among 2,037 intermediate risk TAVR patients (mean age 81.7 years, STS score 5.6%), 8.2% were unable to walk. Baseline 6MWT was associated with allcause mortality over 2 years (Hazard ratio (HR) 0.87 per 50 m, 95% confidence interval [CI] 0.83 to 0.92, p < .0001). Among surviving patients, the adjusted absolute change in 6MWT at 2 years improved for patients unable to walk (+134.1 m, 95% CI 102.1 to 166 m, p < .0001) and slow walkers (+60.5 m, 95% CI 42.8 to 78.2 m, p < .0001), but was unchanged for medium walkers (7.3 m, 95% CI 24.3 to 9.6 m, p = .4), and declined for fast walkers (41.3 m, 95% CI 58.7 to 23.9 m, p < .0001).

 

CONCLUSION - Poor functional capacity is predictive of 2year mortality in elderly intermediate risk patients undergoing TAVR. However, surviving patients with poor baseline functional capacity had significant improvement in 6MWT performance and quality of life at 2years following TAVR.